Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
13.89
-0.30 (-2.11%)
At close: Jan 9, 2026, 4:00 PM EST
13.89
0.00 (0.00%)
After-hours: Jan 9, 2026, 4:45 PM EST
Xencor Employees
Xencor had 250 employees as of December 31, 2024. The number of employees decreased by 30 or -10.71% compared to the previous year.
Employees
250
Change (1Y)
-30
Growth (1Y)
-10.71%
Revenue / Employee
$600,528
Profits / Employee
-$523,292
Market Cap
991.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 250 | -30 | -10.71% |
| Dec 31, 2023 | 280 | -1 | -0.36% |
| Dec 31, 2022 | 281 | 27 | 10.63% |
| Dec 31, 2021 | 254 | 52 | 25.74% |
| Dec 31, 2020 | 202 | 36 | 21.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XNCR News
- 1 day ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire
- 8 days ago - Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 - Seeking Alpha
- 4 weeks ago - Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Business Wire
- 2 months ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript - Seeking Alpha
- 2 months ago - Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - Business Wire
- 2 months ago - Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Business Wire